Clinuvel Pharmaceuticals (CLVLY)

[USS Vengeance]

Post from Seeva222 on Sharescene. An excellent roundup of available info and current status.

What we know
> We have EMA approval
> Universal pricing is almost a reality (FU Germany) - there are many more countries in the queue
> The holdup is capacity, not demand
> GB will be coming online
> We're above the most optimistic AGM forecasts on revenue and the bottom line
> We're fast tracked with the FDA and they've accepted that the risk is acceptable. Efficacy seems to be the only issue and the bar has been lowered on efficacy for the FDA.
> A SE Asia platform has been launched - with a potential massive market. Clinuvel with have a proprietary compound (right language?)
> It looks like there's a clear move to the NASDAQ in the offing and a repositioning toward NA (which will open the doors to JVs and acquisition)
> Revenue numbers and annual report will come out this month

Indications

Solar Urticaria, EPP, Vitiligo, HHD, Actinic Keratosis
Psoriasis http://www.google.sr/patents/WO2015067503A1?cl=en
Acne http://onlinelibrary.wiley.com/doi/10.1111...4658.x/abstract

EPP Market

Cost (in AUD) $22,500

Q3 Implants (est) 1.7
Current | Potential
Quarter Revenue $11,054,250 | $84,705,900

Ann Implants (est) 3.0
Current | Potential
Ann Revenue $19,507,500 | $149,481,000

Current | Potential

USA - | 1,000
Germany 55 | 400
England - | 400
France - | 350
Netherlands 104 | 250
Italy 50 | 50
Norway - | 41
Austria 40 | 40
Switzerland 40 | 40
Sweden - | 40
Belgium - | 40
Czech - | 40
Portugal - | 40
Hungary - | 40
Sweden - | 40
Scotland - | 25
Denmark - | 25
Finland - | 25
Slovakia - | 25
Ireland - | 20

Total 289 | 2,931